Q2(R1)中英文对照.doc
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_05.gif)
《Q2(R1)中英文对照.doc》由会员分享,可在线阅读,更多相关《Q2(R1)中英文对照.doc(117页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、Four short words sum up what has lifted most successful individuals above the crowd: a little bit more.-author-dateQ2(R1)中英文对照REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USEREQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE人用药品的注册要求ICH HARMONISED TRIPARTITE GUIDELINE ICH协调
2、的三方指导原则VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY 分析方法验证:正文和方法学Q2(R1) Current Step 4 version 现行第4阶段版本Parent Guideline dated 27 October 1994 最初指导原则起于1994年10月27日(Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005) (方法学补充指导原则完成于1996年11月6日,于2005年11月
3、合并)This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Ja
4、pan and USA.此指导原则由适当的ICH专家工作组起草,经调整团磋商,于ICH过程一致。在第四阶段,最终的草案推荐给欧盟,日本和美国的监管机构采用。Q2(R1) Document HistoryQ2(R1) 文件历史First Codification 初次法典化History 历史Date 时间New Codification November 2005Parent Guideline: Text on Validation of Analytical Procedures 最初的指导原则:分析方法的验证Q2 Approval by the Steering Committee un
5、der Step 2 and release for public consultation. 在第2阶段经策划委员会批准,作为公用的咨询26 October 2003 2003-10Q2 Q2A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 在第4阶段经侧环委员会同意并推荐给三方ICH监管机构采用27 October 1994 1994-10-27Q2 Guideline on Validation of A
6、nalytical Procedures: Methodology developed to complement the Parent Guideline 分析方法验证的指导原则:扩展的方法学作为最初指导原则的补充Q2B Approval by the Steering Committee under Step 2 and release for public consultation. 在第2阶段经策划委员会批准,作为公用的咨询29 November 1995 in Q2(R1) Q2B Approval by the Steering Committee under Step 4 and
7、 recommendation for adoption to the three ICH regulatory bodies 在第4阶段经侧环委员会同意并推荐给三方ICH监管机构采用Current Step 4 version 现行Q2A and Q2B The parent guideline is now renamed Q2(R1) as the guideline Q2B on methology has been incorporated to the parent guideline. The new title is “Validation of Analytical Proc
8、edures: Text and Methodology”. 最初的指导原则现在更名为Q2(R1)因为指导原则Q2B方法学已经合并到最初的指导原则中。新标题“分析方法验证:正文和方法学”November 2005 Q2(R1) PART I: TEXT ON VALIDATION OF ANALYTICAL PROCEDURES 分析方法验证文件ICH Harmonised Tripartite Guideline ICH协调三方指导原则Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
9、on 27 October 1994, this guideline is recommended for adoption to the three regulatory parties to ICH1994年10月27日的ICH策划委员会会议已经进入了ICH进程的第4阶段,此指导原则推荐给ICH三个监管部门采纳1. Introduction This document presents a discussion of the characteristics for consideration during the validation of the analytical procedure
10、s included as part of registration applications submitted within the EC, Japan and USA. This document does not necessarily seek to cover the testing that may be required for registration in, or export to, other areas of the world. Furthermore, this text presentation serves as a collection of terms,
11、and their definitions, and is not intended to provide direction on how to accomplish validation. These terms and definitions are meant to bridge the differences that often exist between various compendia and regulators of the EC, Japan and USA. 1 介绍作为递交给欧共体,日本和美国新药注册申请资料的一部分,对分析方法验证需考虑事项的特征的讨论在此文件呈现
12、出来。没有必要在此文件寻找覆盖在世界其他地区的药品的注册或出口所要求的测试。此外,此文作为术语的收集,和他们的定义而服务的,并没有想提供怎样完成验证的指示。这些项目和定义是连接那些常存在于欧共体,日本和美国的各种药典和规定之间的差异的桥梁。The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose. A tabular summation of the characteristics applicable to iden
13、tification, control of impurities and assay procedures is included. Other analytical procedures may be considered in future additions to this document. 分析方法验证的目的是为了阐述分析方法是适用于它要分析的目的的。应用于鉴别,杂质控制和含量测定方法的特征项的综合,可能考虑会加入到今后的文件中。2. Types of Analytical Procedures to be Validated 2所要验证的分析方法的类型The discussion
14、 of the validation of analytical procedures is directed to the four most common types of analytical procedures: 分析方法验证的讨论通常集中在以下分析方法的四个最通用的方面:- Identification tests; -鉴别试验;- Quantitative tests for impurities content; -杂质含量的定量测试;- Limit tests for the control of impurities; -杂质控制的限度测试;- Quantitative t
15、ests of the active moiety in samples of drug substance or drug product or other selected component(s) in the drug product.-原料药或制剂或其他药品中选择性的组分的样品的活性部分的定量测试; Although there are many other analytical procedures, such as dissolution testing for drug products or particle size determination for drug subst
16、ance, these have not been addressed in the initial text on validation of analytical procedures. Validation of these additional analytical procedures is equally important to those listed herein and may be addressed in subsequent documents. 虽然有许多其他的分析方法,诸如药品的溶解性试验或药品微粒大小测试,在分析方法验证最初的正文中并未给出。那些额外的分析方法的
17、验证和在这里列出来的分析方法同样重要,且有可能在后来的文件中提出。A brief description of the types of tests considered in this document is provided below. 对于此文件中考虑到的测试的类型的简短描述如下:- Identification tests are intended to ensure the identity of an analyte in a sample. This is normally achieved by comparison of a property of the sample (
18、e.g., spectrum, chromatographic behavior, chemical reactivity, etc) to that of a reference standard; - 鉴别试验是为了鉴定样品中某个分析物存在。通常将适当的样品与参考标准品进行比较(例如,光谱,色谱行为,化学反应等)。- Testing for impurities can be either a quantitative test or a limit test for the impurity in a sample. Either test is intended to accurate
19、ly reflect the purity characteristics of the sample. Different validation characteristics are required for a quantitative test than for a limit test;- 杂质测试是对样品中的杂质进行定性或定量试验。这两种试验都是为了准确的反应样品中杂质的特性。与限度试验相比,定量试验要求不同的验证试验项。- Assay procedures are intended to measure the analyte present in a given sample.
20、 In the context of this document, the assay represents a quantitative measurement of the major component(s) in the drug substance. For the drug product, similar validation characteristics also apply when assaying for the active or other selected component(s). The same validation characteristics may
21、also apply to assays associated with other analytical procedures (e.g., dissolution).- 含量测试方法是为了测定给定样品中的被测物的量。此文件的内容中,含量测试代表原料药中的主成分的定量的测试。对于药物制剂中的活性组分或其他选择性组分进行含量测定时,相似的验证特征也同样应用。同样的验证特征也可以应用到与其他分析方法相关联的含量测试中(如,溶解)。The objective of the analytical procedure should be clearly understood since this wi
22、ll govern the validation characteristics which need to be evaluated. Typical validation characteristics which should be considered are listed below: 分析方法的目的应该清晰易懂,因为它将制约需要被评价的验证特征。应考虑的典型的验证特征如下:Accuracy 准确度Precision 精密度Repeatability 重复性Intermediate Precision 中间精密度Specificity 特异性Detection Limit 检测限Qu
23、antitation Limit 定量限Linearity 线形Range 范围Each of these validation characteristics is defined in the attached Glossary. The table lists those validation characteristics regarded as the most important for the validation of different types of analytical procedures. This list should be considered typical
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Q2 R1 中英文 对照
![提示](https://www.taowenge.com/images/bang_tan.gif)
限制150内